Author | year | Country | Diagnosis | Regimes of anti-lymphoma treatment | Regimes of AT treatment | Follow-up (m) Median (range) | HCV infection | R use in HCV + patients | AT in HCV + patients | Hazard ratio | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
yes | no | yes | no | yes | no | ||||||||
Besson [9] | 2006 | France | DLBCL | – | – | 47 (0–112) | 26 | 5560 | – | – | – | – | Extrapolated |
Chen [10] | 2015 | China | DLBCL | I-CHT | – | 36 (0.84–96.24) | 29 | 139 | 29 | 0 | – | – | Extrapolated |
Chen [11] | 2015 | China | DLBCL | I-CHT | – | – | 22 | 102 | 15 | 7 | – | – | Reported |
Dlouhy [12] | 2017 | Spain | DLBCL | I-CHT | – | 48 (1.2–146.4) | 31 | 290 | 31 | 0 | – | – | Extrapolated |
Elbedewy [13] | 2020 | Egypt | DLBCL | I-CHT | – | – | 76 | 277 | 33 | 43 | 34 | 42 | Reported |
Ennishi [14] | 2010 | Japan | DLBCL | I-CHT | DAA | HCV+ 31 (4–42) HCV− 32 (5–51) | 131 | 422 | 131 | 0 | 7 | 124 | Reported |
Hosry [17] | 2016 | USA | DLBCL | I-CHT | IFN, Rib, DAA | > 6 | 76 | 228 | 76 | 0 | 26 | 40 | Extrapolated |
Nishikawa [29] | 2012 | Japan | DLBCL | I-CHT | – | HCV+ 40.8 (3.6–92.4) HCV− 31.2 (2.4–94.8) | 28 | 220 | 28 | 0 | 0 | 28 | Extrapolated |
Park [16] | 2008 | Korea | DLBCL | I-CHT | – | 37.8 | 32 | 371 | – | – | – | – | Extrapolated |
Shimono [18] | 2019 | Japan | ps-DLBCL | I-CHT | – | HCV + 46.9 (4.0–94.3) HCV− 36.8 (0.8–133.5) | 12 | 46 | 10 | 2- | – | – | Extrapolated |
Ordinary DLBCL | I-CHT | – | HCV+ 27.8 (1.9–122.1) HCV− 35.9 (0.1–90.1) | 25 | 120 | – | – | – | – | Extrapolated | |||
Arcaini [30] | 2007 | Italy | Non-gastric MALToma | CHT, RT, surgery | – | – | 60 | 112 | – | – | – | – | Extrapolated |
Arcaini [31] | 2006 | Italy | SMZL | splenectomy, IFN | – | 37.2 | 49 | 206 | – | – | – | – | – |
Hosry [32] | 2020 | USA | FL | I-CHT, RT | IFN, Rib, DAA | – | 19 | 57 | – | – | 13 | 6 | – |
Nesterova [33] | 2020 | Russia | FL | I-CHT | DAA | – | 11 | 105 | 11 | 0 | 11 | 0 | – |
De Vita [34] | 1997 | Italy | B-NHL | – | – | – | 35 | 122 | – | – | – | – | – |
Luppi [35] | 1998 | Italy | B-NHL | IFN, CHT | – | 72 | 35 | 122 | 0 | 35 | – | – | Extrapolated |
La Mura [36] | 2008 | Italy | NHL | CHT | IFN, Rib | – | 69 | 274 | 0 | 69 | 25 | 44 | Extrapolated |
Strianese [37] | 2010 | Italy | OA lymphoma | I-CHT, RT | – | Mean 75 (12–185) | 23 | 106 | – | – | – | – | Extrapolated |
Tajima [38] | 2017 | Japan | NHL | – | – | – | 66 | 1316 | – | – | – | – | – |
Vallisa [39] | 1999 | Italy | NHL | CHT, surgery | – | 30 (1–68) | 65 | 110 | 0 | 65 | – | – | – |
Arcaini [19] | 2014 | Italy | indolent NHL | surgery, I-CHT, RT | IFN, Rib | 42 (6–204) | 704 | 0 | 126 | 578 | 134 | 570 | Reported |
Merli [15] | 2014 | Italy | DLBCL | surgery, I-CHT, RT | IFN, Rib | 24 (12–168) | 535 | 0 | 255 | 280 | 23 | 512 | Reported |
Michot [20] | 2015 | France | NHL | surgery, I-CHT, RT | IFN, Rib | 31 (19–71) | 116 | 0 | – | – | 70 | 46 | Reported |
Persico [40] | 2018 | Italy | DLBCL | I-CHT | DAA | 12 | 121 | 0 | 70 | 51 | 20 | 101 | Extrapolated |
Rattotti [21] | 2019 | Italy | Indolent NHL | I-CHT, antibiotics | IFN, Rib | 36 (1‐84) | 138 | 0 | – | – | 36 | 102 | Extrapolated |
Aggressive NHL | 112 | 0 | – | – | 17 | 95 | |||||||
Salah-Eldin [41] | 2014 | Egypt | DLBCL | I-CHT | – | 41 (38.6–43.4) | 280 | 0 | 200 | 80 | 0 | 0 | Reported |
Zaky [22] | 2014 | Egypt | DLBCL | I-CHT | – | 36 (5–42) | 137 | 0 | 68 | 69 | – | – | Extrapolated |